Conflict of Interest Disclosures: Dr Rosenberg received a Clinical Trials grant from Pfizer, Novartis, and Janssen and received a US patent for Amyloid- Gene Vaccines seeing that inventor. REFERENCES 1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173C177. [PubMed] [Google Scholar] 2. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408(6815):979C982. [PubMed] [Google Scholar] 3. Gilman S, Koller M, Black RS, et al. AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553C1562. [PubMed] [Google Scholar] 4. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216C223. [PubMed] [Google Scholar] 5. Relkin N, Bettger L, Tsakanikas D, Ravdin L. Three-year follow-up on the IVIG for Alzheimer’s phase II study.. Alzheimer’s Association International Conference; Vancouver, British Columbia, Canada. July 14-19, 2012; Abstract P3-381. [Google Scholar] 6. Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795C804. [PMC free article] [PubMed] [Google Scholar] 7. Qu BX, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol. 2004;61(12):1859C1864. [PMC free article] [PubMed] [Google Scholar] 8. Qu BX, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci. 2006;244(1-2):151C158. [PMC free article] [PubMed] [Google Scholar] 9. Qu BX, Xiang Q, Li L, Johnston SA, Hynan Etomoxir inhibitor database LS, Rosenberg RN. Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci. 2007;260(1-2):204C213. [PMC free article] [PubMed] [Google Scholar] 10. Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stve O, Rosenberg RN. Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer’s disease. Vaccine. 2010;28(32):5280C5287. [PMC free article] [PubMed] [Google Scholar] 11. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stve O, Rosenberg RN. DNA beta-amyloid (1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA. 2009;302(16):1796C1802. [PMC free article] [PubMed] [Google Scholar] 12. Etomoxir inhibitor database Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer’s disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol. 2011;31(6):867C874. [PMC free article] [PubMed] [Google Scholar] 13. Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation A42 DNA vaccine for Alzheimer’s disease. J Neuroimmunol. 2013;254(1-2):63C68. [PMC free article] [PubMed] [Google Scholar] 14. Lambracht-Washington D, Rosenberg RN. Active DNA A42 vaccination as immunotherapy for Alzheimer disease. Translational Neurosci. 2012;3(4):307C313. [PMC free article] [PubMed] [Google Scholar] 15. Rosenberg RN. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry. 2005;62(11):1186C1192. [PMC free article] [PubMed] [Google Scholar]. US patent for Amyloid- Gene Vaccines as inventor. REFERENCES 1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like Etomoxir inhibitor database pathology in the PDAPP mouse. Nature. 1999;400(6740):173C177. [PubMed] [Google Scholar] 2. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a style of Alzheimer’s disease. Character. 2000;408(6815):979C982. [PubMed] [Google Scholar] 3. Gilman S, Koller M, Dark RS, et al. AN1792(QS-21)-201 Research Team. Clinical ramifications of Abeta immunization (AN1792) in individuals with AD within an interrupted trial. Neurology. 2005;64(9):1553C1562. [PubMed] [Google Scholar] 4. Holmes C, Boche D, Wilkinson D, et al. Long-term ramifications of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled stage I trial. Lancet. 2008;372(9634):216C223. [PubMed] [Google Scholar] 5. Relkin N, Bettger L, Tsakanikas D, Ravdin L. Three-year follow-up on the IVIG for Alzheimer’s stage II research.. Alzheimer’s Association International Meeting; Vancouver, British Columbia, Canada. July 14-19, 2012; Abstract P3-381. [Google Scholar] 6. Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical Etomoxir inhibitor database and biomarker adjustments in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795C804. [PMC free content] [PubMed] [Google Scholar] 7. Qu BX, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol. 2004;61(12):1859C1864. [PMC free content] [PubMed] [Google Scholar] 8. Qu BX, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces mind amyloid plaque burden in transgenic mice. J Neurol Sci. 2006;244(1-2):151C158. [PMC free content] [PubMed] [Google Scholar] 9. Qu BX, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccine helps prevent Abeta42 deposition in mind of dual transgenic mice. J Neurol Sci. 2007;260(1-2):204C213. [PMC free of charge content] [PubMed] [Google Scholar] 10. Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stve O, Rosenberg RN. Evaluation of three plasmid systems for make use of in DNA A beta 42 immunization as therapy for Alzheimer’s disease. Vaccine. 2010;28(32):5280C5287. [PMC free content] [PubMed] [Google Scholar] 11. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stve O, Rosenberg RN. DNA beta-amyloid (1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA. 2009;302(16):1796C1802. [PMC free of charge content] [PubMed] [Google Scholar] 12. Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 offers high potential as secure therapy for Alzheimer’s disease since Il1a it diminishes antigen-particular Th1 and Th17 cellular proliferation. Cellular Mol Neurobiol. 2011;31(6):867C874. [PMC free of charge content] [PubMed] [Google Scholar] 13. Lambracht-Washington D, Qu BX, Fu M, et al. A peptide prime-DNA increase immunization process provides significant benefits as a fresh generation A42 DNA vaccine for Alzheimer’s disease. J Neuroimmunol. 2013;254(1-2):63C68. [PMC free of charge content] [PubMed] [Google Scholar] 14. Lambracht-Washington D, Rosenberg RN. Energetic DNA A42 vaccination as immunotherapy for Alzheimer disease. Translational Neurosci. 2012;3(4):307C313. [PMC free of charge content] [PubMed] [Google Scholar] 15. Rosenberg RN. Translational study on the path to effective therapy for Alzheimer disease. Arch Gen Psychiatry. 2005;62(11):1186C1192. [PMC free of charge content] [PubMed] [Google Scholar].